Plasmodium falciparum antigens inducing protective antibodies
AssigneeInstitut Pasteur
InventorsPierre Druilhe, Hasnaq Bouharoun-Tayoun, Claude Oeuvray
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to a purified polyclonal or monoclonal antibody which recognizes an epitope of a protein of 48,000 dalton, where the protein recognizes is a surface protein of a merozoite of Plasmodium falciparum which has a peptide of SEQ ID NO:1 or a sequence wherein SEQ ID NO:1 has been modified by insertion, deletion or substitution and the sequence inhibits the binding of monoclonal antibody 245 to Plasmodium merozoites, as well as fragments of the antibody; the present invention relates to composition and kits containing the same, as well as methods of using the same.
Claims11
1-30. (canceled)
A method for treating Plasmodium falciparum by passive immunotherapy, comprising administering to a mammal in need thereof, a composition comprising a polyclonal or monoclonal antibody, wherein the polyclonal or monoclonal antibody recognizes an epitope of a protein of 48,000 daltons, wherein the protein is a surface protein of a merozoite of Plasmodium falciparum which comprises a peptide of SEQ ID NO:
- 1 or a sequence of SEQ ID NO:
- 1 which has been modified by insertion, deletion, or substitution provided that the sequence inhibits the binding of monoclonal antibody 245 to Plasmodium merozoites.
The method of claim 33, wherein the monoclonal or polyclonal antibody recognizes a peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.
Dependencies are inferred from the claim text.